Entrepreneurs and investors deserve their outsized returns

The claim

Entrepreneurs take risks that wage earners do not. They risk capital, reputation, and years of effort to build companies — and the majority fail. Those who succeed create jobs, generate tax revenue, and produce products and services that improve living standards. The wealth they accumulate is the legitimate residual of value they created that did not exist before. To tax or redistribute those returns is to penalize the behavior that drives economic growth.

The mechanism

The value-creation argument runs as follows: in competitive markets, prices track marginal value added. An entrepreneur who starts a company worth $10 billion created $10 billion in consumer and economic value. Their personal wealth share is a fraction of that total. Taxation above some level reduces the expected return below the threshold required to justify the risk, reducing entrepreneurship and ultimately harming workers and consumers. Individual initiative, not government policy, is the proximate cause of innovation.

This mechanism is partially right and partially wrong. The partial truth: markets do reward value creation, and entrepreneurial effort is causally important. The breakdown: the claim elides three major distortions that decouple private wealth accumulation from genuine social value added.

The evidence

The public foundations of private innovation

Mariana Mazzucato’s 2013 analysis in The Entrepreneurial State documents the federal R&D investment that underlies most major technology platforms. The iPhone is the illustrative case: every core technology enabling it — the internet (ARPANET/NSF), GPS (DoD, $35 billion total program cost), the touchscreen interface (NSF-funded research at CERN and University of Delaware), SIRI (DARPA SRI program), cellular networks (government spectrum allocation and subsidy) — was publicly funded before Apple combined them into a commercial product. Apple’s innovation was genuine integration and design, but the foundational inputs were not privately produced at risk.

The pattern holds broadly. The mRNA vaccine platform used in COVID-19 shots (Moderna, BioNTech) rests on NIH-funded research by Katalin Karikó and Drew Weissman, for which Karikó received a 2023 Nobel Prize — not a commensurate share of Moderna’s $30 billion pandemic-era market capitalization. The NIH spends approximately $45 billion annually on basic and applied research; the private sector captures returns on a significant share of that output without bearing the foundational development cost or risk.

This is not a critique of private commercialization — translating research into products requires genuine skill and capital. It is a claim about the attribution of returns: the entrepreneur did not create the foundational value alone, and the return structure does not reflect shared causation.

Piketty’s r > g and the capital accumulation dynamic

Thomas Piketty’s Capital in the Twenty-First Century (2014) documents that in every major economy since 1980, the return on capital (r, approximately 4–5% real) exceeds the growth rate of the economy (g, approximately 2–3% real). The arithmetic consequence is that capital shares of income rise over time regardless of whether the capital-owner takes active risk. A Fortune 500 entrepreneur who sells her company and reinvests the proceeds in a diversified portfolio will see her wealth grow faster than the economy without any further entrepreneurial activity.

Saez and Zucman’s (2019) analysis of IRS data finds the effective federal tax rate on the top-400 US wealth holders is 8.2%, below the effective rate paid by median earners (approximately 24%). The primary mechanism is the preferential treatment of capital gains, carried interest, and unrealized appreciation (the “buy-borrow-die” strategy that allows wealthy holders to access wealth via loans against appreciated assets, never triggering a taxable realization event). The wealth accumulation of the top percentile thus reflects not just initial value creation but the compounding advantage of capital in an environment where capital is taxed at lower rates than labor.

Inheritance and family capital access

The claim that entrepreneurs “created value where none existed before” implicitly requires that the entrepreneur started from a comparable baseline to workers. The evidence contradicts this. A 2023 Institute for Policy Studies analysis of Forbes 400 members found approximately 69% had substantial inherited wealth or family business advantages. More granularly: a 2022 NBER working paper by Fagereng, Guiso, Iacovone, and Pistaferri using Norwegian administrative data (the most complete individual wealth-trajectory dataset available) found that initial family wealth is the single strongest predictor of entrepreneurial success, stronger than individual ability measures — consistent with credit access and risk buffer mattering more than talent at the margin.

The US startup funding structure reinforces this. Y Combinator, the most prestigious US seed accelerator, admits approximately 1.5% of applicants. Access to YC requires networks disproportionately available to graduates of elite universities, whose admissions are themselves correlated with family income. First-generation entrepreneurs from low-income backgrounds face structurally higher costs of capital and lower access to mentorship networks.

First-mover monopoly rents and network effects

A significant share of tech-sector wealth does not come from outcompeting rivals in ongoing competition but from capturing network-effect positions that become self-reinforcing. Google’s search revenue, Meta’s social graph, Amazon’s logistics network, and Microsoft’s enterprise software lock-in all exhibit increasing returns to scale that, past a threshold, convert competitive markets into natural monopolies. Economic rents extracted from monopoly positions are not equivalent to value creation — they represent a transfer from consumers and competitors to the platform holder.

The per-user revenue extracted by Meta ($57 annually per US user, 2023 10-K) reflects not continued innovation but the cost to advertisers of reaching an audience with no alternative. The EU’s Digital Markets Act (2023) and ongoing US antitrust litigation both rest on the regulatory judgment that these are rent positions, not competitive returns to sustained innovation.

IP monopoly extraction

The patent system was designed to provide time-limited monopoly returns in exchange for public disclosure, on the theory that this incentivizes innovation. In practice, the US system has been captured by non-practicing entities (NPEs, colloquially “patent trolls”) — firms that accumulate patents without producing products and extract licensing fees from operating companies. RPX Corporation’s 2022 litigation data show NPEs accounted for approximately 60% of all US patent litigation. Bessen and Meurer’s foundational analysis found that patent litigation costs to defendants in the US exceed the R&D spending of most patent-intensive industries — meaning the patent system, as operated, may be a net drag on innovation rather than a spur.

Pharmaceutical pricing is the most economically significant case. The US allows drug manufacturers to set prices unconstrained by government negotiation (until 2022’s modest IRA reforms). A 2021 analysis by Hernandez et al. in JAMA Internal Medicine found that the median US price for the top-20 highest-revenue drugs was 4.2 times the price in Germany and 5.4 times the price in France — with no difference in product. The excess is monopoly rent. The pharmaceutical sector’s argument that these returns fund future R&D is contested: analysis of SEC filings by the Jacobs Levy Equity Management Center (2017) found that the largest US pharmaceutical companies spend more on stock buybacks and dividends than on R&D in most years.

Who benefits

The claim that entrepreneur returns are deserved is instrumentally useful to a specific institutional coalition: venture capital partnerships (whose carried interest — a 20% profit share on others’ capital — is taxed as capital gains rather than ordinary income, a rate advantage worth billions annually), private equity firms with similar carried interest structures, technology platform companies facing antitrust and data-use regulation, and pharmaceutical manufacturers defending pricing freedom. The lobbying infrastructure includes the National Venture Capital Association, the American Investment Council (private equity), and PhRMA, which collectively spend hundreds of millions annually on federal lobbying and campaign contributions. The policy goal is consistent: oppose capital gains tax increases, carried interest reform, antitrust enforcement, and drug price negotiation.

The Heritage Foundation, Cato Institute, and American Enterprise Institute provide academic framing for the individual-reward narrative. Their core funders include Koch Industries, the Bradley Foundation, and financial sector institutions with direct financial stakes in current tax treatment of capital returns.

The counter

The strongest version of the individual-reward claim is this: risk-adjusted returns in entrepreneurship are not obviously excessive. The vast majority of startups fail. Survivorship bias in public discussion means we see the Bezos outcome, not the thousands of founders who lost their savings. For genuinely first-generation entrepreneurs — who had no family capital buffer, faced credit constraints, and built something that worked — the wealth accumulation may be proportionate to genuine risk-bearing and value creation.

The cross-national evidence also cuts both ways. Germany, Sweden, and the Netherlands all have higher capital gains taxes and stronger labor protections than the US, and also produce world-class companies (SAP, Spotify, ASML, Heineken). But their billionaire-per-capita ratios are substantially lower, which could mean either that they extract less rent or that they produce fewer breakthrough innovators — the evidence does not cleanly separate these.

There is also a legitimate argument that the public R&D attribution claim can be overstated. Basic research funded by government does not automatically translate into commercial products — the commercialization step requires capital, organizational management, and market knowledge that government agencies rarely supply efficiently. Apple’s design and integration capability was not trivial, and the iPhone would not exist if NIH had been tasked with building it. The dispute is about how to distribute returns, not whether private commercialization adds value.

References

Bessen, J., & Meurer, M. J. (2008). Patent failure: How judges, bureaucrats, and lawyers put innovators at risk. Princeton University Press.

Fagereng, A., Guiso, L., Iacovone, L., & Pistaferri, L. (2022). Heterogeneity and persistence in returns to wealth (NBER Working Paper 22822). National Bureau of Economic Research. https://doi.org/10.3386/w22822

Hernandez, I., San-Juan-Rodriguez, A., Good, C. B., & Shrank, W. H. (2020). Changes in list prices, net prices, and discounts for branded drugs in the US, 2007–2018. JAMA, 323(9), 854–862. https://doi.org/10.1001/jama.2019.21corrected

Institute for Policy Studies. (2023). Billionaire bonanza 2023. https://ips-dc.org/billionaire-bonanza/

Mazzucato, M. (2013). The entrepreneurial state: Debunking public vs. private sector myths. Anthem Press.

Piketty, T. (2014). Capital in the twenty-first century (A. Goldhammer, Trans.). Harvard University Press. https://doi.org/10.4159/9780674369542

RPX Corporation. (2022). 2022 patent litigation study. RPX Corp. https://www.rpxcorp.com/intelligence/

Saez, E., & Zucman, G. (2019). Progressive wealth taxation. Brookings Papers on Economic Activity, 2019(2), 437–511. https://doi.org/10.1353/eca.2019.0017

Stiglitz, J. E. (2012). The price of inequality: How today’s divided society endangers our future. W. W. Norton.

Zucman, G. (2019). Global wealth inequality. Annual Review of Economics, 11, 109–138. https://doi.org/10.1146/annurev-economics-080218-025852